Meningiomas, which arise from the sphenoid wing and spread to the orbital cavity and inner cranial region, Spheno-Orbital Meningiomas (SOMs) are a unique type of meningiomas. Protheragen offers comprehensive diagnostics and therapeutics development services for SOM, leveraging cutting-edge technologies and expertise in molecular biology and drug development.
Spheno-orbital meningioma, SOM for short, is an uncommon form of meningioma that develops on the sphenoid wing and projects into the orbit. While benign in nature, SOMs may severely impinge on the quality of life of patients because of their placement, causing much morbidity due to their severe location in regard to the eyes, alongside proptosis and various neurological deficits. SOMs constitute about nine percent of intracranial meningiomas and are usually found in middle-aged females. Their complex anatomical location poses unique challenges for diagnosis and therapy, necessitating advanced therapeutic strategies.
Fig.1 Example of histopathological analysis of SOM. (Liu Y., et al., 2024)
The development of Spheno-Orbital Meningiomas stems from several factors ranging from genetic and anatomical to environmental influences. These tumors arise from the arachnoid cap cells of the meninges and demonstrate various degrees of histological manifestations, such as the WHO Grade II meningiomas, which are aggressive and have high recurrence rates. The tumors also extend posteriorly and laterally due to the rich vascular supply of the sphenoid wing and its closeness to the orbit and skull base.
Anti-Angiogenic Agents
SOM growth is managed, and tumor vascularity is reduced with the administration of Bevacizumab which is a monoclonal antibody targeting VEGF. This suggests that the antibody has some degree of effectiveness against SOMs.
mTOR Inhibitors
The suppression of tumor growth in SOMs with the NF2 mutation is being studied with Everolimus, a powerful mTOR inhibitor.
Hormonal Therapies
In SOMs with a positive progesterone receptor, an anti-tumor effect is observed with Mifepristone, which is a progesterone receptor antagonist.
Being a prominent research services company, Protheragen strives to move the area of Spheno-Orbital Meningioma diagnostics and therapeutics forward by offering innovative research and development services. We are embarking on the integration of modern molecular biology with preclinical and animal model development, which will ensure proper diagnosis and adequate therapy development.
Protheragen's preclinical research services for SOM include the development of robust in vitro and in vivo models, high-throughput screening of therapeutic candidates, and detailed pharmacokinetics and toxicology studies. If you are interested in our services, please feel free to contact us.
References
Copyright © 2025 Protheragen. All rights reserved.